Department of Medical Imaging and Radiological Technology, Yuanpei University, Hsinchu, Taiwan.
Department of Clinical Laboratory Sciences and Medical Biotechnology, National Taiwan University, Taipei, Taiwan; Department of Laboratory Medicine and Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Leuk Res. 2014 May;38(5):625-31. doi: 10.1016/j.leukres.2014.03.008. Epub 2014 Mar 19.
Let-7a-3 transcribes the miRNA let-7a, of which the expression is dysregulated in cancer. We evaluated the significance of let-7a-3 gene methylation in patients with de novo acute myeloid leukemia (AML). Let-7a-3 was methylated in 81.1% (73/90), partially methylated in 12.2% (11/90), or unmethylated in 6.7% (6/90) of patients. Let-7a-3 methylation correlated with AML karyotyping and CCAAT/enhancer binding protein α (CEBPA) methylation. Kaplan-Meier survival analysis predicted that let-7a-3 hypermethylation correlated with better survival in AML with hypomethylated CEBPA or with hypomethylated CEBPA without the favorable karyotype. We conclude that let-7a-3 methylation is a positive prognosticator for AML patients with hypomethylated CEBPA.
Let-7a-3 转录 miRNA let-7a，其表达在癌症中失调。我们评估了新诊断的急性髓系白血病 (AML) 患者中 let-7a-3 基因甲基化的意义。在 90 例患者中，let-7a-3 发生甲基化的占 81.1%（73/90），部分甲基化的占 12.2%（11/90），未甲基化的占 6.7%（6/90）。Let-7a-3 甲基化与 AML 核型和 CCAAT/增强子结合蛋白α（CEBPA）甲基化相关。Kaplan-Meier 生存分析预测，let-7a-3 高甲基化与 CEBPA 低甲基化或 CEBPA 低甲基化且核型不良的 AML 患者的生存改善相关。我们的结论是，let-7a-3 甲基化是 CEBPA 低甲基化的 AML 患者的一个有利预后因素。
